On December 8, 2025 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the Company’s senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird’s Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET. Dr. Harrison is Professor of Myeloproliferative Neoplasms, Clinical Director at Guy’s and St. Thomas’ NHS Foundation Trust and a leading international expert in myelofibrosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source, and will be available for replay following the event.

(Press release, Karyopharm, DEC 8, 2025, View Source [SID1234661262])

On December 8, 2025 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, and along with its subsidiaries, hereafter referred to as "Dr. Reddy’s"), reported that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Efti is Immutep’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Efti is also being investigated in other indications including head & neck cancer, breast cancer, and soft tissue sarcoma.

The terms of the licensing agreement provide Immutep with significant milestones and preserves its ability to capture material future upside in the licensed markets as efti advances commercially. Further, Immutep holds the global manufacturing rights to the product across all markets and will supply the product to Dr. Reddy’s in the licensed markets, while Immutep retains all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.

Additionally, as per the agreement, Immutep will receive from Dr. Reddy’s an upfront payment of USD 20 million (~AUD 30.2 million). It is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales in these markets.

"This collaboration marks our continuous efforts to deliver first-in-class and innovative therapies for cancer treatment. Efti is a novel immunotherapy with the potential to set a new standard of care in combination with pembrolizumab (Keytruda) and chemotherapy as first-line therapy for non-small cell lung cancer. Its broad potential extends to other major cancers across multiple stages of disease. Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialization of this promising cancer therapy in the licensed markets," stated M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s.

"This agreement with Dr. Reddy’s marks a significant milestone for Immutep and further validates the potential of efti. Dr. Reddy’s proven capabilities and reach in the licensed markets make them an ideal partner to maximise the impact of our innovation and serve a large number of patients across the globe. Additionally, this partnership allows us to capture significant value for efti in the licensed markets, while retaining full rights in key markets such as North America, Europe, and Japan, and ensures we remain very well-positioned for future value creation," said Marc Voigt, CEO of Immutep.

About Eftilagimod Alfa (Efti):

Efti is a first-in-class soluble LAG-3 protein and MHC Class II agonist delivered subcutaneously that uniquely activates antigen-presenting cells or APCs (e.g., dendritic cells, monocytes) via major histocompatibility complex (MHC) class II ligands. As an MHC Class II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important co-stimulatory signals & cytokines that further boost the immune system’s ability to combat cancer.

Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC) in a pivotal Phase III trial called TACTI-004 (KEYNOTE-F91), as well as head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile enables various combinations like with anti-PD-[L]1 immunotherapy, radiotherapy, and/or chemotherapy. This has been demonstrated across early-stage trials in NSCLC and HNSCC, which have laid the foundation for the larger randomized clinical trial in NSCLC. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).

(Press release, Immutep, DEC 8, 2025, View Source [SID1234661279])

On December 8, 2025 BostonGene, developer of the leading AI foundation model for cancer and the immune system, reported seven abstracts have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS) 2025, taking place from December 9–12, 2025, in San Antonio, Texas. The research, conducted in collaboration with leading cancer centers, demonstrates the power of the BostonGene platform to uncover complex breast cancer tumor biology and drive informed, personalized treatment strategies. BostonGene will exhibit at booth #1352.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster spotlight discussions:

Poster spotlight number: PD7-03
Title: Circulating immune correlates of pathological response to neoadjuvant pembrolizumab plus chemotherapy in high-risk, early-stage triple-negative breast cancer
Date & time: December 11, 2025; 7:36 AM – 7:39 AM
Presenter: Clinton Yam, MD, MS, The University of Texas MD Anderson Cancer Center

Using BostonGene’s multi-parameter immune phenotyping platform and immunotype signature scores, clinicians at MD Anderson profiled peripheral blood from patients with triple-negative breast cancer (TNBC) undergoing the KEYNOTE-522 regimen. This study showed immune cells in the blood were significantly associated with improved response to KEYNOTE-522. Identified through BostonGene’s natively omnimodal AI model, these immune signatures show promise as minimally invasive biomarkers to identify patients most likely to respond to immune-based neoadjuvant approaches, supporting patient stratification and optimization of therapy in TNBC.

Research done in collaboration with MD Anderson Cancer Center

Poster spotlight number: PD7-09
Title: Feasibility of a machine learning (ML)-based peripheral blood immunoprofiling platform to stratify patients (pts) with early-stage triple-negative breast cancer
Date & time: December 11, 2025; 8:06 AM – 8:09 AM
Presenter: Chiara Corti, MD, Dana-Farber Cancer Institute

BostonGene’s machine learning-based immune phenotyping platform was used to examine blood samples of early-stage triple-negative breast cancer (TNBC). BostonGene’s platform assessed how immune profiles differed between chemotherapy alone and chemotherapy plus immunotherapy, and how they evolved during treatment. Immunotype distribution varied significantly by therapy type and showed dynamic changes, particularly in patients receiving chemo-immunotherapy. These findings support the feasibility of capturing immune dynamics in peripheral blood as a minimally invasive approach to refine patient stratification, improve trial design and inform treatment optimization in early-stage TNBC.

Research done in collaboration with Brigham and Women’s Hospital

Poster presentations:

Presentation number: PS1-09-12
Title: TROP2 expression and therapeutic opportunities in inflammatory breast cancer
Date & time: December 10, 2025; 12:30 PM – 2:00 PM
Presenter: Shayla Murray, MD Anderson Cancer Center

Collaborative research utilizing BostonGene’s foundation AI platform revealed that TROP2 RNA expression alone does not predict antibody-drug conjugate response in inflammatory breast cancers, underscoring the limitations of single-marker approaches. These findings demonstrate the necessity of BostonGene’s AI-driven omnimodal analysis built to uncover complex tumor biology and optimize clinical trial design for next-generation precision oncology therapies.

Research done in collaboration with MD Anderson Cancer Center

Presentation number: PS2-10-30
Title: Tumor-associated macrophage (TAMs) and cancer-associated fibroblasts (CAFs) profiles in invasive lobular carcinoma (ILC) vs no special type (NST)
Date & time: December 10, 2025; 5:00 PM – 6:30 PM
Presenter: Jason Mouabbi, MD, MD Anderson Cancer Center

BostonGene performed a large-scale analysis of 617 ILC and NST breast cancers, leveraging its AI-driven KassandraTM algorithm to deconvolve hundreds of cell subtypes and activation states from RNA data within the tumor microenvironment (TME). Similar to NST, ILC samples harbored immunosuppressive, stroma-rich TMEs dominated by FAP⁺ myofibroblastic CAFs and M1/M2 TAMs, identifying previously unknown opportunities for targeted therapeutics and novel immune strategies in this often understudied cancer.

Research done in collaboration with MD Anderson Cancer Center

Presentation number: PS2-10-16
Title: Distinct immune landscapes in inflammatory and metaplastic breast cancer: Insights from transcriptomic profiling
Date & time: December 10, 2025; 5:00 PM – 6:30 PM
Presenter: Elyse R. Lopez, MD Anderson Cancer Center

BostonGene’s multimodal model, which integrates genomic, transcriptomic, and immunologic data, was used to analyze 444 invasive, inflammatory and metaplastic breast cancer samples. The analysis revealed distinct clinically relevant immune landscapes in both cancers, illustrating BostonGene’s ability to deliver reliable insights for treatment decision-making and optimal trial design.

Research done in collaboration with MD Anderson Cancer Center

Presentation number: PS2-09-24
Title: Aurora kinase A (AURKA) A new druggable target in ER+ inflammatory breast cancer
Date & time: Wednesday, December 10, 2025; 5:00 PM – 6:30 PM
Presenter: Tanu Sharma, PhD, MD Anderson Cancer Center

Researchers at MD Anderson applied BostonGene’s comprehensive pipeline to analyze RNA and DNA samples from ER+ inflammatory breast cancer (IBC) tumors, revealing amplified expression of AURKA in IBC tumors and the potential for synthetic lethality, where therapeutic targeting of AURKA alongside another target could lead to cell death. These findings demonstrate BostonGene’s capability in integrating genomic and transcriptomic data with clinical outcomes to generate biologically grounded, actionable insights.

Research done in collaboration with MD Anderson Cancer Center

Presentation number: PS4-01-10
Title: Characterizing CCR7 gene amplification and protein expression in inflammatory and non-inflammatory breast cancer
Date & time: Thursday, December 11, 2025: 5:00 PM – 6:30 PM
Presenter: Surbhi Shivhare, PhD, MD Anderson Cancer Center

BostonGene, in collaboration with MD Anderson, applied its multimodal model to examine both CCR7 copy number alterations and gene expression in inflammatory breast cancer. This comprehensive study uncovered discordance across CCR7 copy numbers and RNA levels and pointed to the potential impact of membranous CCR7 protein toward disease status. Highlighting BostonGene’s target discovery applications, this study identified CCR7 as a promising therapeutic target for aggressive breast cancer.

Research done in collaboration with MD Anderson Cancer Center

(Press release, BostonGene, DEC 8, 2025, View Source [SID1234661295])

On December 8, 2025 Akari Therapeutics presented its corporate presentation (Presentation, Akari Therapeutics, DEC 8, 2025, View Source [SID1234661247]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 8, 2025 Kian Immune Cell, a knowledge-based biotechnology company specializing in cellular cancer therapies, in collaboration with the Barekat Comprehensive Cancer Hospital, reported it is honored to host the scientific seminar titled "Innovations in Cancer Treatment Using Immune Cells."
This seminar aims to bring together leading oncologists in Tehran, offering a valuable platform to review and discuss the latest advancements in cancer treatment through immune cell–based approaches.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Featured Speakers and Presentation Topics
A distinguished panel of experts will deliver talks covering emerging scientific and clinical developments:

Dr. Payam Azadeh: Overview of the seminar’s objectives
Dr. Abolhassan Shahzadeh Fazeli: The role of next-generation sequencing (NGS) in cancer detection and molecular identification
Dr. Mohammad Faranoush: Recent advancements in cancer immunotherapy and evolving therapeutic strategies
Dr. Mohammad Sadegh Najafi: Presentation by the esteemed representative of Behestan Darou
Dr. Reza Nakooeian: Examination of tumor growth mechanisms with a focus on genetics and epigenetics
Dr. Marzieh Ebrahimi: Insights into tumor immunology and immune cell–based therapeutic approaches for malignant solid tumors
Dr. Delbar Daneshjoo / Dr. Mobina Ghasemi: Case-based review of NK cell therapies, presenting clinical findings and long-term follow-up outcomes
These presentations collectively offer a comprehensive overview of cutting-edge scientific progress in cellular and immune-based cancer treatment.

Seminar Details
Date: Thursday, December 10, 2025 (20 Azar 1404)
Time: 08:00 to 14:00
Venue: Conference Hall, Barekat Comprehensive Cancer Hospital
Capacity: Limited; early registration is strongly recommended
Contact: For coordination, please call +98-21-92001360, extension 508

(Press release, Kian Immune Cell, DEC 8, 2025, View Source [SID1234661263])